General Updates

Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel : 0124 492 1033 Fax : 0124 492 1041 Emergency : 105010 Email : secretarial@fortishealthcare.com Website : www.fortishealthcare.com August 5, 2026 FHL/SEC/2026-27 The National Stock Exchange of India Ltd. BSE Limited Scrip Symbol: FORTIS Scrip Code: 532843 Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Madam / Sir, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), this is to inform you that the Board of Directors of Agilus Diagnostics Limited (a material subsidiary of the Company) in its meeting held today i.e. August 5, 2026, concluded at 04:30 PM has approved an intra-group restructuring involving merger of its (direct or indirect) wholly owned subsidiaries - Agilus Pathlabs Private Limited and DDRC Agilus Pathlabs Limited (collectively referred to as the “Subsidiaries”), into Agilus Diagnostics Limited, by way of a Scheme of Arrangement (“Scheme”), subject to the terms and conditions thereof. As is customary, the Scheme will be subject to the approval of the jurisdictional National Company Law Tribunals (“NCLTs”) or any other relevant authority (as may be required), and the members and creditors of the companies. Given the Scheme is an intra-group restructuring involving merger of wholly owned subsidiaries, no consideration will be payable pursuant to the Scheme. This is for your information and records. Thanking you, Yours Sincerely, For Fortis Healthcare Limited Satyendra Chauhan Company Secretary & Compliance Officer M. No. – A14783 FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel : 0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933